Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Prilosec OTC (omeprazole-magnesium) Clear all
Terminated Phase 3 Interventional Results available

Treating H. Pylori in Parkinson's Patients With Motor Fluctuations

NCT00664209
View directory record Official record
Conditions
Parkinson's Disease, Helicobacter Infections, Motor Fluctuations
Interventions
clartihromycin, amoxicillin, and omeprazole, placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 5, 2026, 6:18 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Anti-reflux Control to Decrease Post Tonsillectomy Pain

NCT01777854
View directory record Official record
Conditions
Laryngopharyngeal Reflux, Throat Pain
Interventions
Omeprazole
Drug
Lead sponsor
Ascension Health
Industry
Eligibility
7 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Grand Blanc, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Phase 1 Interventional

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors

NCT01218620
View directory record Official record
Conditions
Adult Solid Neoplasm
Interventions
Gamma-Secretase Inhibitor RO4929097, Ketoconazole, Rifampin, Midazolam Hydrochloride, Omeprazole, Tolbutamide, Dextromethorphan Hydrobromide, Pharmacological Study, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Gastric Acid on Colonic Microbiome

NCT01901276
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Omeprazole 40 mg bid
Drug
Lead sponsor
Daniel Freedberg, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression

NCT00903448
View directory record Official record
Conditions
Healthy
Interventions
Prilosec OTC (omeprazole-magnesium), Prevacid
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 31, 2010 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects

NCT02922933
View directory record Official record
Conditions
Volunteers, Healthy Volunteers, Human Volunteers, Normal Volunteers
Interventions
entinostat, Omeprazole, Famotidine
Drug · Dietary Supplement
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

NCT02453022
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults

NCT05319912
View directory record Official record
Conditions
Healthy
Interventions
ALXN1840 Enteric-coated Tablet, ALXN1840 Non-coated Capsule, Omeprazole
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study

NCT00942136
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GSK1349572, Placebo, Omeprazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2009 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Phase 2 Interventional Results available

IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity

NCT02609386
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oral Cavity
Interventions
IRX-2, Cyclophosphamide, Indomethacin, Zinc-containing multivitamin, Omeprazole
Biological · Drug · Dietary Supplement
Lead sponsor
Brooklyn ImmunoTherapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
13
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clopidogrel Pharmacogenetics (PGX) Bench to Bedside

NCT01341600
View directory record Official record
Conditions
Metabolism of Clopidogrel
Interventions
Clopidogrel, Omeprazole/Clopidogrel
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
20 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Phase 2 Interventional Results available

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

NCT00001337
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma, Anaplastic Large-Cell Lymphoma, Gray Zone Lymphoma
Interventions
Etoposide, Rituximab, Prednisone, Cyclophosphamide, Vincristine, Doxorubicin, MRI, CT, Biopsy, PET scan, Laparotomy, Ondansetron, Prochlorperazine, Omeprazole, Docusate Sodium + Sennosides, Lactulose
Drug · Biological · Diagnostic Test + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2024
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations

NCT02790840
View directory record Official record
Conditions
Healthy
Interventions
Omeprazole, Gefapixant
Drug
Lead sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Phase 4 Interventional Results available

Implementation of PPI Medication PGX Testing

NCT02794844
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Genotype Guided PPI Dosing
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
2 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Phase 4 Interventional Results available

Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?

NCT01093755
View directory record Official record
Conditions
Inflammation, Barrett's Esophagus
Interventions
dexlansoprazole, Omeprazole
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 5, 2026, 6:18 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

NCT02760615
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Phase 3 Interventional

Management of Myocardial Injury After Noncardiac Surgery Trial

NCT01661101
View directory record Official record
Conditions
Myocardial Injury After Noncardiac Surgery (MINS)
Interventions
Dabigatran, Placebo (for Dabigatran), Omeprazole, Placebo (for Omeprazole)
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
45 Years and older
Enrollment
1,754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
Kansas City, Kansas • Buffalo, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Oct 5, 2026, 6:18 PM EDT
Withdrawn Not applicable Interventional

Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)

NCT02039869
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Non Erosive Reflux Disease, Dyspepsia
Interventions
Confocal endomicroscopy, Proton pump inhibitor, Sucralfate
Device · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Kenner, Louisiana • Charleston, South Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 5, 2026, 6:18 PM EDT
Recruiting Phase 4 Interventional

The Mechanism Versus PPI Trial

NCT06999577
View directory record Official record
Conditions
Laryngopharyngeal Reflux, Cough, Throat Clearing, Dysphonia, Reflux
Interventions
Omeprazole 40 MG, Laryngeal Recalibration Therapy, GERD Lifestyle Recommendations
Drug · Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 89 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Deigo, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 5, 2026, 6:18 PM EDT
Recruiting Phase 4 Interventional

OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers

NCT05799105
View directory record Official record
Conditions
Marginal Ulcer
Interventions
Omeprazole 40 milligrams
Drug
Lead sponsor
Stephen Firkins
Other
Eligibility
Not listed
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Gastric pH and Anthocyanin Absorption

NCT01122160
View directory record Official record
Conditions
Anthocyanin Metabolism
Interventions
omeprazole, placebo
Drug
Lead sponsor
USDA Beltsville Human Nutrition Research Center
Federal
Eligibility
22 Years to 59 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Beltsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Voxelotor CYP and Transporter Cocktail Interaction Study

NCT05981365
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Voxelotor, Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, Metformin, Furosemide, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Phase 4 Interventional Results available

Placebo In Chronic Back Pain (Phase 2)

NCT02986334
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Naproxen, Omeprazole, Placebo
Drug
Lead sponsor
Apkar Apkarian
Other
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 5, 2026, 6:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers

NCT00446004
View directory record Official record
Conditions
Healthy
Interventions
Imatinib Mesylate, Omeprazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 5, 2026, 6:18 PM EDT